Heart disease remains the leading cause of death worldwide. The proliferation of heart issues — paired with lifestyle factors that complicate patient recruitment and study design — reflect an urgent need for expert-led clinical trials.
Moreover, intersections among heart health and metabolic research offer promising opportunities to confront diseases affecting a growing, aging population, and will require multidisciplinary expertise to conduct effective clinical trials.
William Cromwell, MD, FAHA, FNLA, shares his perspective on how targeted treatments are reshaping cardiometabolic research, and why now is an ideal moment to leverage expertise at scale. As a leader of the Cardiometabolic CARE Council, and Principal Investigator at our site in Durham, NC, Dr. Cromwell is a longtime thought leader in lipoprotein disorders and cardiovascular disease.
